Company profile
Qilu Pharmaceutical
Large vertically-integrated Chinese pharma (FDF + API manufacturer)
Privately held: no public share price · China
Assets
(18 total)
18Total Assets
0Approved
10Phase 3 / Filed
8Phase 1–2 / Early
8Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Dopamine D2 and serotonin 5-HT2A/5-HT2C receptors (antagonist); mu-opioid receptor (antagonist) · Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule | Schizophrenia | |
| Phase 3 | PD-1Monoclonal antibody | Non-Small Cell Lung Cancer | |
| Phase 3 | PD-1 x CTLA-4Multispecific antibody | Non-Small Cell Lung Cancer | |
| Phase 3 | IL-4R-alphaMonoclonal antibody | Atopic Dermatitis | |
| Phase 3 | CD38Monoclonal antibody | Multiple Myeloma | |
| Phase 3 | PCSK9RNA / oligonucleotide | Atherosclerotic Cardiovascular Disease | |
| Phase 3 | Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist) · Dopamine D3/D2 receptor (partial agonist)Small molecule | Schizophrenia | |
| Phase 3 | JAKSmall molecule | Atopic Dermatitis | |
| Phase 3 | GPRC5D x CD3Multispecific antibody | Multiple Myeloma | |
| Phase 3 | ALK;ROS1Small molecule | Non-Small Cell Lung Cancer | |
| Phase 2 | IRAK4Small molecule | Atopic Dermatitis | |
| Phase 2 | Aldosterone synthase (CYP11B2)Small molecule | Hypertension | |
| Phase 2 | GPRC5D x BCMA x CD3Multispecific antibody | Multiple Myeloma | |
| Phase 1/2 | KRAS G12DSmall molecule | Non-Small Cell Lung Cancer | |
| Phase 1/2 | KAT6A / KAT6BSmall molecule | Breast Cancer HR+/HER2- Metastatic Breast Cancer |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.